New Zealand - English - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - mesalazine 1 g;  ; mesalazine 1 g - modified release granules - 1 g - active: mesalazine 1 g   excipient: acetone ethylcellulose microcrystalline cellulose purified water active: mesalazine 1 g excipient: acetone ethylcellulose povidone purified water - treatment of mild to moderate ulcerative colitis

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية الفياصل - al-faiasel drug store - nystatin 1 g, iodochloro-hydroxyquin 3 g, hydrocortisone acetate 1 g - 1 g, 3 g, 1 g

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

pharmalink store france - 1 hdpe bottle with 180 g of powder + 3 measuring spoons (1g, 150mg, 100mg) - powder - 1g/g - urinary system-cystitis

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة العربية لصناعة الادوية المساهمة الخاصة - the arab pharmaceutical manufacturing psc - ceftazidime 1 g - 1 g

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - cefazolin sodium 1048mg equivalent to cefazolin 1 g - powder for injection - 1 g - active: cefazolin sodium 1048mg equivalent to cefazolin 1 g

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - ceftazidime pentahydrate, quantity: 1175 mg (equivalent: ceftazidime, qty 1000 mg) - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime for injection is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. ,indications include the following:,severe infections in general: ,for example: septicaemia including neonatal sepsis, bacteraemia; and in patients in intensive care units with specific problems, e.g., infected burns.,respiratory tract infections: ,for example: pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis.,severe ear, nose and throat infections: ,for example: otitis media, mastoiditis.,urinary tract infections: ,for example: acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones.,skin and soft tissue infections: ,for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis.,gastrointestinal and abdominal infections: ,for example: intra-abdominal abscesses, enterocolitis.,bone and joint infections: ,for example: osteitis, osteomyelitis, septic arthritis, infected bursitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cefepime, quantity: 1000 mg - injection, powder for - excipient ingredients: arginine - adults:. cefepime is indicated in the treatment of the infections listed below when caused by susceptible bacteria.. - lower respiratory tract infections, including pneumonia and bronchitis;. - urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections;. - skin and skin structure infections;. - intra-abdominal infections, including peritonitis and biliary tract infections;. - gynaecological infections;. - septicaemia;. - empirical treatment in febrile neutropenic patients (see precautions).. cefepime is also indicated for surgical prophylaxis in patients undergoing intra-abdominal surgery. in this indication it is essential that metronidazole also be administered.. paediatrics:. cefepime is indicated in paediatric patients over 2 months of age for the treatment of the infections listed below when caused by susceptible bacteria. . - urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections;. - skin and skin structure infections;. - septicaemia;. - empirical treatment in febrile neutropenic patients (see precautions).. culture and susceptibility studies should be performed when appropriate to determine susceptibility of the causative organism(s) to cefepime. empirical therapy with cefepime may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly.. because of its broad spectrum of bactericidal activity against gram positive and gram negative bacteria, cefepime can be used appropriately as monotherapy prior to identification of the causative organisms(s). in the treatment of febrile neutropenia, consideration should be given to the need for other antibiotics in combination with cefepime. in patients who are at risk of mixed aerobic/ anaerobic infection, including infections in which bacterioides fragilis may be present, concurrent initial therapy with an anti-anaerobic agent is recommended before the causative organism(s) is known.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cefazolin sodium, quantity: 1048 mg - injection, powder for - excipient ingredients: - cefazolin is indicated in the treatment of the following serious infections due to susceptible organisms:,respiratory tract infections due to s. pneumoniae, klebsiella species, h. influenzae, staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci.,injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever.,cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present.,genitourinary tract infections due to esch. coli, pr. mirabilis, klebsiella species, and some strains of enterobacter and enterococci.,skin and skin structure infections due to staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci and other strains of streptococci.,bone and joint infections due to staph. aureus.,septicaemia due to s. pneumoniae, staph. aureus (penicillin-sensitive and penicillin-resistant), pr. mirabilis, esch. coli and klebsiella species.,endocarditis due to staph. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-haemolytic streptococci.,appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cefazolin sodium, quantity: 1048 mg - injection, powder for - excipient ingredients: - cefazolin is indicated in the treatment of the following serious infections due to susceptible organisms:,respiratory tract infections due to s. pneumoniae, klebsiella species, h. influenzae, staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci.,injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever.,cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present.,genitourinary tract infections due to esch. coli, pr. mirabilis, klebsiella species, and some strains of enterobacter and enterococci.,skin and skin structure infections due to staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci and other strains of streptococci.,bone and joint infections due to staph. aureus.,septicaemia due to s. pneumoniae, staph. aureus (penicillin-sensitive and penicillin-resistant), pr. mirabilis, esch. coli and klebsiella species.,endocarditis due to staph. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-haemolytic streptococci.,appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin.

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - aztreonam 1 g; aztreonam 1 g - powder for injection - 1 g - active: aztreonam 1 g excipient: arginine active: aztreonam 1 g excipient: arginine - for the treatment of infections caused by susceptible gram-negative microorganisms. it has been used successfully to treat: urinary tract infections (including pyelonephritis and cystitis (initial and recurrent) and asymptomatic bacteriuria, including those due to the pathogens resistant to the aminoglycosides, cephalosporins or penicillins); lower respiratory tract infections (including pneumonia and bronchitis); bacteraemia/septicemia; bone and joint infections; skin and skin-structure infections (including those associated with postoperative wounds, ulcers and burns); intra-abdominal infections (including peritonitis); gynaecologic infections (including pelvic inflammatory disease, endometritis, and pelvic cellulitis); gonorrhoea (acute uncomplicated urogenital or anorectal infections due to beta-lactamase producing or non-producing strains of n.gonorrhoeae). before instituting treatment with azactam, appropriate specimens should be obtained for isolation of the causative organism(s) and for determination of susceptibility to aztreonam. treatment with azactam may be started empirically before results of the susceptibility testing are available. concurrent therapy: in seriously ill patients, additional antibiotic therapy should be initiated concurrently with azactam to provide broad-spectrum coverage before identification and susceptibility testing results of the causative organism(s) are known. some patients with serious pseudomonas infections may benefit from concurrent use of azactam and an amino-glycoside because of synergistic action. these agents are also synergistic in vitro against many strains of enterobacteriaceae, and other gram-negative aerobic baccilli. however, this enhanced activity is not predictable.